The present invention relates to quinazolinone compounds of the formula ##STR00001## whereinR.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification and in the claims, in free form or in salt form, processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.